Category: Pfizer

Did COVID vaccines kill 14X more people than they saved?

Did a study just show that COVID-19 vaccines killed 14x more people than they saved?! Take a look at the viral claim, and find out what the facts really are!   Claim : COVID Vaccines Kill 14X More People Than They Saved! People are sharing an article (archive) by The…

Continue Reading Did COVID vaccines kill 14X more people than they saved?

16 UK biotech companies you should know about

The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023, the UK biotech scene is now one of the most vibrant in Europe, laying the…

Continue Reading 16 UK biotech companies you should know about

Top antibody-drug conjugate (ADC) companies leading the industry

The antibody-drug conjugate (ADC) field is witnessing an expansion in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms of action. Investments in ADC research continue to grow, with significant funding rounds and acquisitions. For example, Novo Holdings’ $105…

Continue Reading Top antibody-drug conjugate (ADC) companies leading the industry

The promising horizon of hair loss treatments

There hasn’t been a lot of hair loss treatment progress in the last twenty years. However several biotech companies are hot on the case and are getting tantalizingly close to the breakthrough that many patients hope for. With body dysmorphia magnified by the omnipresent digital world, psychiatrists have increasingly linked…

Continue Reading The promising horizon of hair loss treatments

Biotech job market 2024: what to expect?

The past year saw a string of pipeline cuts and downsizing plans strike the biotech job market. Have layoffs spooked young professionals looking for a way into the industry, and does the employment landscape seem to be looking up this year? Employment in the life sciences industry had hit a…

Continue Reading Biotech job market 2024: what to expect?

Federal secrets spill on COVID origins amid rodent research on risks of lab mods, vax in pregnancy

The National Institutes of Health appears to be struggling to hide its dirty laundry on COVID-19 origins against a rash of leaks, congressional probes, and Freedom of Information Act requests, even when officials are determined to thwart sunlight. The ongoing exposure of their communications and actions isn’t the only thing…

Continue Reading Federal secrets spill on COVID origins amid rodent research on risks of lab mods, vax in pregnancy

2 low-priced gene therapy stocks to speculate on

Key Points bluebird bio has three FDA-approved gene therapy treatments that are planning to commercialize after its $150 million secondary offering of common shares priced at $1.50 per share. bluebird bio’s latest FDA approval, LYFGENIA, is a one-time treatment for sickle cell disease, which is priced around $3.1 million per…

Continue Reading 2 low-priced gene therapy stocks to speculate on

Amid second-largest wave of COVID infections in the US, Florida’s surgeon general calls to halt mRNA vaccines

On Friday, wastewater data from Biobot Analytics and the US Centers for Disease Control and Prevention (CDC) affirmed that the US has now reached its second-highest level of COVID-19 infections of the pandemic. It is anticipated that by midweek, rates of infections will reach 2 million per day with approximately…

Continue Reading Amid second-largest wave of COVID infections in the US, Florida’s surgeon general calls to halt mRNA vaccines

The best countries for biotech according to the OECD

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech companies (2,840) and an R&D intensity added value of 17%, the U.S. remains a strong leader in the industry. But…

Continue Reading The best countries for biotech according to the OECD

Five AI drug discovery companies you should know about

Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the industry now embracing the technology, we take a look at five of the top AI drug discovery companies.  The…

Continue Reading Five AI drug discovery companies you should know about

80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

Job Category Any CategoryJobInternshipWork from Home Job Type Any Job TypesFull-timePart-timeContractVolunteer Location Any CountryUKCanadaAustraliaPakistanIrelandGermanyUSASwedenNew ZealandMalaysiaRussiaNetherlandDubaiSwitzerlandJapanVietnamItalyDenmarkOnlineGeorgiaLatviaSingaporeChinaNetherlandsIndiaFranceBelgiumBrazilColombiaEuropeEstoniaThailandNorwayNigeriaQatarCambodiaUAESouth KoreaAustriaTurkeyworldwideADB CountriesIndonesiaSaudi Arabia Industry Any Industry athletic apparel and footwear Refugee AgencyAccredited registrarAeronauticsAerospaceAirlineappliance manufacturerArtificial Intelligencearts, entertainment, and recreation sectorAstronomical ResearchAutomationAutomativeAviationBankingBioinformaticsBroadcastingBusiness Administrationcar manufacturingchemicalCivic and Social OrganizationsCivil EngineeringConsumer goodsCreativity and Innovation DevelopmentCyber SecurityDairyingData analyticsDevelopmentDigitale-commerceEducationEducationElectric Power GenerationEnergyEngineeringEngineering Professional…

Continue Reading 80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

TCW’s Top Twenty: Why I don’t believe there ever was a Covid virus

As we approach the end of the year, we are repeating our twenty most-read articles of 2023, in reverse order. This is number 2 and it was first published on March 22. I’VE grown increasingly frustrated about the way debate is controlled around the topic of origins of the alleged…

Continue Reading TCW’s Top Twenty: Why I don’t believe there ever was a Covid virus

The race for RSV vaccine development and approval in 2023

It has been a bumpy ride for biopharma to develop a vaccine for the potentially deadly respiratory syncytial virus (RSV), since the 1960s. As GSK and Pfizer battled it out earlier this year, with the former’s Arexvy vaccine crowned the first-ever RSV vaccine to hit the market, a mere few…

Continue Reading The race for RSV vaccine development and approval in 2023

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Old convertible cars for sale near me

Catalytic converters are an important part of a car’s emission system, and they can be recycled for scrap metal. Selling catalytic converter scrap can be a lucrative business, but there are a few things to consider in order to maximize prof…1968 Oldsmobile 442 Beautiful Vintage Convertible! 75,894km Specs: Engine Size…

Continue Reading Old convertible cars for sale near me

Viral Vectors and Plasmid DNA Manufacturing market is

Visiongain has published a new report entitled Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034: Forecasts by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), by Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology), by End-use (Pharma and Biopharma Companies, Research Institutes), by Disease (Oncology, Genetic Disorders,…

Continue Reading Viral Vectors and Plasmid DNA Manufacturing market is

Synthetic Biology Industry Charts Course for a Remarkable US$138.8 Billion Valuation by 2032-FMI Study

Intradermal Injection Industry The value of the worldwide synthetic biology industry size was estimated at US$ 15.8 billion in 2022 and is projected to grow to around US$ 138.8 billion by 2032. Synthetic biology refers to redesigning organisms through engineering with the objective of improving development in health services and…

Continue Reading Synthetic Biology Industry Charts Course for a Remarkable US$138.8 Billion Valuation by 2032-FMI Study

FDA Fails to Address DNA Adulteration Concerns

The following article originally appeared on Dr. Robert Malone’s Substack, and is reprinted here verbatim with permission. Robert Malone, MD, MS; Malone Institute December 15, 2023, 2:30 PM EST (Madison VA and Tallahassee FL) The failure of government regulatory authorities to identify and disclose DNA fragment contamination of…

Continue Reading FDA Fails to Address DNA Adulteration Concerns

Brace yourselves for these trends in clinical research in 2024

There’s an air of cautious optimism about 2024, after a difficult few years following the end of the pandemic when investment in pharma and biotech research dropped substantially. After this significant reset, there’s now hope that in 2024, in line with emerging trends, the funds will be there for the…

Continue Reading Brace yourselves for these trends in clinical research in 2024

A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

Targeted therapy regimen, BRAFTOVI® (encorafenib) in combination with cetuximab, included on MOH Cancer Drug List, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer who have received prior systemic therapy. BRAFTOVI in combination with cetuximab has been included on MOH CDL, for patients with BRAFV600E-mutant metastatic colorectal cancer…

Continue Reading A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore | Taiwan News

FDA Suggests Florida Surgeon General Is Spreading “Misinfo” About COVID Vax Safety

Florida Surgeon General Dr. Joseph Ladapo As the federal government renews calls for more COVID-19 vaccines, the Biden administration continues to argue that the jabs are safe and effective, and said suggestions to the contrary, such as those recently expressed by Florida’s top doctor, amount to “misinformation and disinformation” that…

Continue Reading FDA Suggests Florida Surgeon General Is Spreading “Misinfo” About COVID Vax Safety

FDA Fails to Address DNA Adulteration Concerns, Resorting To Gaslighting Instead

Thanks, Jan! Lets get this amplified! Go Joe Ladapo! t.co/kgaIolmKnR — Robert W Malone, MD (@RWMaloneMD) December 16, 2023 Someone said: “If reports I’ve read in the news are correct, that many high level members of the FDA are heavily invested in the covid vaccines, then it make sense that…

Continue Reading FDA Fails to Address DNA Adulteration Concerns, Resorting To Gaslighting Instead

Lipid Nanoparticles (LNPs) CDMO Market Latest Trends and Future Opportunities Analysis to 2031

“Global Lipid Nanoparticles (LNPs) CDMO Market Focus on Nucleic Acids LNPs Segmented By Product (mRNA , Plasmid DNA (pDNA), siRNA, saRNA, microRNA, and Others), Scale Of Operation (Preclinical, Clinical , and Commercial), End-Users (Pharmaceutical Companies, Academic Research Institute, and Diagnostic Laboratories)- Trends, Industry Competition Analysis, Revenue and Forecast To 2030.”…

Continue Reading Lipid Nanoparticles (LNPs) CDMO Market Latest Trends and Future Opportunities Analysis to 2031

False claim Moderna admitted mRNA vaccines cause cancer

Scientists win Nobel Prize for mRNA, COVID-19 work Dr. Katalin Karikó and Dr. Drew Weissman won the Nobel Prize in Physiology or Medicine for their work on mRNA vaccines, leading to a COVID vaccine. The claim: Moderna admitted mRNA vaccines cause cancer A Dec. 2 Instagram post (direct link, archive…

Continue Reading False claim Moderna admitted mRNA vaccines cause cancer

FDA responds to Ladapo letter

In response to a letter in which Florida Surgeon General Joseph Ladapo noted the detection of DNA fragments in mRNA COVID-19 vaccines, Peter Marks, director of the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research, emphasized the FDA’s view that the shots are safe and effective. “I…

Continue Reading FDA responds to Ladapo letter

Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Turns out Jay Bradner is moving from academia and Novartis to serve as Amgen’s new CSO. Also, the FDA has a new registry of trial sponsors and investigators…

Continue Reading Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

FDA official shames FL surgeon general for raising ‘DNA contamination’ concerns in COVID vaccines

Questioning the purity of mRNA COVID-19 vaccines is tantamount to spreading disinformation that kills people, the FDA’s top vaccines official not so subtly implied to Florida Surgeon General Joseph Ladapo this week. Ladapo notified FDA Commissioner Robert Califf and CDC Director Mandy Cohen Dec. 6 of recent research awaiting peer…

Continue Reading FDA official shames FL surgeon general for raising ‘DNA contamination’ concerns in COVID vaccines

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

ABSTRACT Introduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology. Methods: We included exceptional responders and controls with advanced pancreatic cancer from Cleveland Clinic from April 2013 to August…

Continue Reading Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Bluebird claims big insurer will cover its sickle cell therapy

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to promenade with the official mascot, tidy up up the official…

Continue Reading Bluebird claims big insurer will cover its sickle cell therapy

The latest on Moderna, Apellis, and Merck

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business. The need-to-know this morning Apellis Pharmaceuticals said a…

Continue Reading The latest on Moderna, Apellis, and Merck

CDC director visits Orlando to encourage vaccination, combat misinformation

Centers for Disease Control and Prevention Director Dr. Mandy Cohen traveled to Orlando this week as part of a nationwide tour to combat vaccine misinformation during respiratory disease season. Doctors this year are recommending a flu vaccine, an updated COVID-19 booster, and, for those who qualify, the newly available vaccine…

Continue Reading CDC director visits Orlando to encourage vaccination, combat misinformation

Pfizer to trim sales, R&D budgets as part of $500M more in cuts next year

Pfizer execs said Wednesday that an ongoing cost-cutting plan will expand by $500 million, as the pharma giant looks to lower expenses ahead of its $43 billion Seagen integration and adjust for the post-COVID era.  In 2024, the drugmaker expects $4 billion in savings versus an original expectation of $3.5…

Continue Reading Pfizer to trim sales, R&D budgets as part of $500M more in cuts next year

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13…

Continue Reading Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Exclusive interview: Florida Surgeon General Joseph Ladapo asks FDA for data on risks of DNA contaminants in COVID-19 vaccines

Florida Surgeon General Joseph Ladapo | Photo courtesy of FDOH BY JENNIFER CABRERA TALLAHASSEE, Fla. – On December 6, Florida Surgeon General Joseph Ladapo sent a letter to the U.S. Food and Drug Administration (FDA), asking questions about a recent preprint documenting the detection of billions of DNA fragments per…

Continue Reading Exclusive interview: Florida Surgeon General Joseph Ladapo asks FDA for data on risks of DNA contaminants in COVID-19 vaccines

Elrexfio can treat relapsed and refractory multiple myeloma in EU

The European Commission has granted conditional marketing authorization to Elrexfio (elranatamab) to treat adults with multiple myeloma who received at least prior three lines of therapy and whose cancer has worsened since their last therapy. The indication covers patients on all 27 countries of the European Union, as well as…

Continue Reading Elrexfio can treat relapsed and refractory multiple myeloma in EU

European Bioinformatics Institute | EMBL-EBI hiring Machine Learning Data Scientist in Hinxton, England, United Kingdom

Open Targets (OT) is a unique public-private partnership working to deliver experimental data and informatics platforms that enable researchers to make more informed decisions about target selection for drug discovery. OT is a shared initiative between the European Bioinformatics Institute (EMBL-EBI), a global leader in the management, integration and analysis…

Continue Reading European Bioinformatics Institute | EMBL-EBI hiring Machine Learning Data Scientist in Hinxton, England, United Kingdom

Five Dubai Biopharma Companies To Know About

The Middle East’s industry is rapidly growing, with several key players emerging in the region. Notably, Qatar, Saudi Arabia, and the United Arab Emirates (UAE) are at the forefront of this expansion. Our focus today zeros in on the UAE, particularly Dubai and its biopharma companies, renowned for being one…

Continue Reading Five Dubai Biopharma Companies To Know About

Fact Check: Moderna Did NOT ‘Confirm’ That Its mRNA COVID-19 Vaccines Cause Cancer

Didn’t Happen Did Moderna admit that its COVID-19 mRNA vaccines cause cancer? No, that’s not true: Moderna made no such admission that its COVID mRNA vaccines are contaminated, nor that that they cause cancer or birth defects. There is no publicly available credible evidence that any mRNA vaccines cause cancer,…

Continue Reading Fact Check: Moderna Did NOT ‘Confirm’ That Its mRNA COVID-19 Vaccines Cause Cancer

Fla. Surgeon General Seeks Answers on DNA Contamination of Covid Shots

bymuratdeniz/iStock/Getty Images Plus Florida’s Surgeon General, Dr. Joseph Ladapo, is seeking an explanation from federal health authorities on the undisclosed presence of potentially dangerous DNA fragments in mRNA Covid-19 injections. Ladapo sent a letter to U.S. Food and Drug Administration (FDA) Commissioner Dr. Robert Califf and the U.S. Centers…

Continue Reading Fla. Surgeon General Seeks Answers on DNA Contamination of Covid Shots

DNA Contamination of COVID Vaccines Explored in Journal of American Physicians and Surgeons

DNA Contamination of COVID Vaccines Explored in Journal of American Physicians and Surgeons TUCSON, Ariz., Dec. 11, 2023 (GLOBE NEWSWIRE) — The current controversy over the alleged DNA contamination of COVID-19 vaccines involves complex issues, and also shows the difficulties in arriving at truth in today’s polarized and politicized atmosphere,…

Continue Reading DNA Contamination of COVID Vaccines Explored in Journal of American Physicians and Surgeons

how to obtain a valid patent?

The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process…

Continue Reading how to obtain a valid patent?

Red Biotechnology Market Size, Share, Growth Report and Forecast 2024-2032

PRESS RELEASE Published December 11, 2023   According to the report by Expert Market Research (EMR), the global red biotechnology market is projected to grow at a CAGR of 6.20% between 2024 and 2032. Aided by the escalating demand for therapeutic solutions, innovative drugs, and genetic engineering, the market is expected to…

Continue Reading Red Biotechnology Market Size, Share, Growth Report and Forecast 2024-2032

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Continue Reading Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

There’s Finally Confirmation Of DNA Fragments In The Covid mRNA Shots

BREAKING: Florida’s Surgeon General Joseph Ladapo has confirmed that fragments of DNA have been detected in COVID mRNA shots. What we’ve been saying about the COVID jab for years is finally coming to light. pic.twitter.com/IHZOVIFFgV — Dr. Simone Gold (@drsimonegold) December 10, 2023 More experts addressed the vaccines, saying that…

Continue Reading There’s Finally Confirmation Of DNA Fragments In The Covid mRNA Shots

Pioneer Behind mRNA Vaccines Reveals Plans For Cancer Immunization Shot – What Could Go Wrong?

What could go wrong? The pioneer behind mRNA vaccines has revealed plans for a new vaccine that immunizes against cancer more than a decade before it strikes. pic.twitter.com/Am6B0wm0kr — Dr. Kat Lindley (@KLVeritas) December 9, 2023 Someone said: “First it will be 95% effective. Then 89%, then 77%, and so…

Continue Reading Pioneer Behind mRNA Vaccines Reveals Plans For Cancer Immunization Shot – What Could Go Wrong?

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients with hemophilia A and B without inhibitors, respectively Consistent reduction in bleeding rates observed after an additional 16 months of follow-up in the trial’s long-term extension observational study NEW YORK–(BUSINESS WIRE)– Pfizer…

Continue Reading Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2

Study design, ethical statement, and sample collection The vaccinated participants were recruited under the COVID-19 PROTECT study (2012/00917). The convalescent plasma samples were collected from subjects who were diagnosed with COVID-19 by positive polymerase chain reaction (PCR) results (study 2020/00120). All participants provided written informed consent in accordance with the…

Continue Reading Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2

US FDA approves two gene therapies for sickle cell disease | National

(Reuters) — The U.S. Food and Drug Administration (FDA) on Friday approved two gene therapies for sickle cell disease, making one of them the first treatment in the United States based on the Nobel Prize-winning CRISPR gene editing technology. Casgevy, developed by partners Vertex Pharmaceuticals and CRISPR Therapeutics, and bluebird…

Continue Reading US FDA approves two gene therapies for sickle cell disease | National

FDA Approves Historic CRISPR Based Gene Therapies For Sickle Cell Disease

According to the reports in the media, the U.S. Food and Drug Administration (FDA) announced on Friday its approval of two gene therapies for sickle cell disease, marking a historic milestone in the treatment landscape. Notably, one of the approved treatments, Casgevy, employs the Nobel Prize-winning CRISPR gene editing technology,…

Continue Reading FDA Approves Historic CRISPR Based Gene Therapies For Sickle Cell Disease

Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “Bladder Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline…

Continue Reading Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

No Significant Differences at 5 Year Follow-Up Between Palbociclib-Based Treatment Regimens

Results from the PARSIFAL-LONG study investigating endocrine-sensitive hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer demonstrated the efficacy of 2 combined option therapies, palbociclib (Ibrance; Pfizer) plus letrozole (Femara; Novartis) and palbociclib plus fulvestrant (Faslodex; Hikma), as first-line treatments for metastatic breast cancer. The study found no significant differences in progression-free survival…

Continue Reading No Significant Differences at 5 Year Follow-Up Between Palbociclib-Based Treatment Regimens

Pfizer, Valneva conclude recruitment for Phase 3 trial for Lyme Disease Vaccine candidate VLA15

New York: Pfizer Inc. and Valneva SE have announced that they have completed recruitment for the Phase 3 trial Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) for Lyme disease vaccine candidate VLA15. The trial builds on previous positive Phase 1 and 2 trial results and includes both adult and…

Continue Reading Pfizer, Valneva conclude recruitment for Phase 3 trial for Lyme Disease Vaccine candidate VLA15

COVID vaccine purchases: Romania’s former health minister Vlad Voiculescu charged with abuse of office

Vlad Voiculescu, Romania’s minister of health between December 2020 and April 2021, has officially been charged with abuse of office and complicity in abuse of office in the case targeting the purchase of significantly more COVID-19 vaccine doses than necessary during the pandemic. Anticorruption (DNA) prosecutors started an investigation into…

Continue Reading COVID vaccine purchases: Romania’s former health minister Vlad Voiculescu charged with abuse of office

B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the B-Cell Lymphomas pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphomas pipeline therapeutics…

Continue Reading B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

In Vitro Diagnostics Market Size Estimated to Reach USD 124.65 Bn by 2032| Precedence Research

OTTAWA, ON, Dec. 8, 2023 /PRNewswire/ — The global in vitro diagnostics (IVD) market size is estimated to reach around USD 124.65 billion by 2032, increasing from USD 107.76 billion in 2023. The global in vitro diagnostics (IVD) market size was estimated at USD 115.48 billion in 2022 and the sector has…

Continue Reading In Vitro Diagnostics Market Size Estimated to Reach USD 124.65 Bn by 2032| Precedence Research

Why claims of a new ‘genetic vaccine’ being given to Australian children don’t align with reality

CheckMate December 8, 2023 This week, we debunk viral social media posts that claim a new “genetic vaccine” has been added to the national vaccine schedule for children aged 2-6 months. We also show why the “mother of all revelations” was more fizzer than Pfizer, and identify some of the…

Continue Reading Why claims of a new ‘genetic vaccine’ being given to Australian children don’t align with reality

Bio Europe 2023: the highlights

The biopharma community met at Munich in Germany for BIO-Europe 2023, where attendees from across the world took part in networking events to foster collaboration, last month. With a turnout of nearly 6000 participants and more than 150 exhibitors, the event hosted a number of panel discussions. In collaboration with…

Continue Reading Bio Europe 2023: the highlights

Ladapo letter DNA fragments COVID-19 vaccines

Florida Surgeon General Joseph Ladapo, who notes that DNA fragments have been detected in mRNA COVID-19 vaccines, has issued a letter asking questions related to the issue. “On today’s episode of: What the FDA… I asked @DrCaliff_FDA to address the DNA fragments detected in mRNA COVID shots & how they…

Continue Reading Ladapo letter DNA fragments COVID-19 vaccines

Glioma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “Glioma Pipeline Insight 2023” report provides comprehensive insights about 190+ companies and 130+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product…

Continue Reading Glioma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Blau syndrome Market Scope and overview

Blau syndrome Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report provides an overview including definitions, applications, product launches, developments, challenges, and regions. It is predicted that the market will show strong development due to the driven consumption in various…

Continue Reading Blau syndrome Market Scope and overview

Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

Market Overview and Report Coverage Anaplastic Large Cell Lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that primarily affects the lymph nodes and skin. It is characterized by the abnormal growth of large cells called anaplastic lymphoma kinase (ALK)-positive or ALK-negative lymphoma cells. The ALCL therapeutics market pertains to…

Continue Reading Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Joyce O’Shaughnessy, MD The addition of pembrolizumab (Keytruda) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses (pCRs) in patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer, including subsets defined by geography, stage, baseline clinical lymph node involvement, and PD-L1 expression, according to data…

Continue Reading Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Understanding Risks and Training Needs for Outpatient Bispecific Usage

Robert Mancini, PharmD, BCOP, FHOPA BMT/Heme Pharmacy Program Coordinator PGY2 Oncology Pharmacy Residency Director St. Luke’s Cancer Institute Boise, ID [Read Part 1] Targeted Oncology: Which bispecific T-cell engagers [BiTEs] are now available for use in hematologic malignancies? MANCINI: There are 6 BiTEs currently on the market; we didn’t include…

Continue Reading Understanding Risks and Training Needs for Outpatient Bispecific Usage

Former Romanian PM officially investigated in corruption case targeting COVID vaccine purchases

The National Anticorruption Directorate (DNA) announced on December 6 that it started the criminal investigation against former prime minister Florin Cîțu for complicity in abuse of office. The case targets the purchase of significantly more COVID-19 vaccine doses than necessary during the pandemic, although Romania could have used the opt-out…

Continue Reading Former Romanian PM officially investigated in corruption case targeting COVID vaccine purchases

Roche’s bid to build a better Piqray yields phase 3 breast cancer win, opening door to regulators

Roche’s pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle. The drugmaker’s attempt to improve on Novartis’ Piqray and deliver a first-line PI3K inhibitor has yielded an improved progression-free survival (PFS) in phase 3, teeing up talks with regulatory authorities.  The investigational…

Continue Reading Roche’s bid to build a better Piqray yields phase 3 breast cancer win, opening door to regulators

Pfizer, after delay, completes enrollment in Lyme vaccine trial

Dive Brief: Pfizer and partner Valneva announced Monday that they have finished enrolling participants in a Phase 3 trial evaluating their experimental vaccine for Lyme disease. The announcement ends a lengthy delay that began in February, when the two companies said they were removing half of trial participants due to…

Continue Reading Pfizer, after delay, completes enrollment in Lyme vaccine trial

Clinical Oncology Next Generation Sequencing Market Expected to Grow at a CAGR of 15.86% from 2023 to 2031

InsightAce Analytic Pvt. LTd. Companies covered in this report are Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Myriad Genetics, Perkin Elmer, Caris Life Sciences, Partek, Inc., Eurofins Scientific, and Qiagen N.V., Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Beijing Genomics Institute (BGI), Takara…

Continue Reading Clinical Oncology Next Generation Sequencing Market Expected to Grow at a CAGR of 15.86% from 2023 to 2031

FDA Shuts Down Enquiries About DNA Contamination In COVID Vaccines

Authored by Maryanne Demasi via The Brownstone Institute, The recent findings of DNA fragments in the Pfizer and Moderna Covid-19 vaccines has led many to question why the FDA, which is responsible for monitoring the quality and safety of the vaccines, has failed to sound the alarm. For years, the FDA has…

Continue Reading FDA Shuts Down Enquiries About DNA Contamination In COVID Vaccines

Pfizer, Valneva Finish Phase 3 Trial Recruitment for Lyme Vaccine

9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025 Pfizer aims to submit regulatory filings in the U.S. and Europe in 2026 New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE:…

Continue Reading Pfizer, Valneva Finish Phase 3 Trial Recruitment for Lyme Vaccine

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025 Pfizer aims to submit regulatory filings in the U.S. and…

Continue Reading Pfizer and Valneva Complete Recruitment for Phase 3 VALOR

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025 Pfizer aims to submit regulatory filings in the U.S. and Europe in 2026 New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE:…

Continue Reading Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

Wegovy Maker Paid $25.8M To US Doctors, Experts Over Past Decade

A Reuters analysis finds that Novo Nordisk spent at least $25.8 million over the past decade on U.S. medical professionals to promote its two anti-obesity drugs. They money was party of the drugmaker’s campaign to convince U.S. doctors to prescribe Wegovy and persuade insurers to pay for it. Reuters: Maker…

Continue Reading Wegovy Maker Paid $25.8M To US Doctors, Experts Over Past Decade

Pfizer Abandons Twice-Daily Weight-Loss Drug: Is the Stock in Trouble?

Pfizer (NYSE:PFE), a global pharmaceutical giant, recently faced a setback in its quest to capture a significant share of the burgeoning weight loss drug market. The company announced its decision to discontinue the development of a twice-daily version of its experimental weight loss pill, danuglipron, following mixed results…

Continue Reading Pfizer Abandons Twice-Daily Weight-Loss Drug: Is the Stock in Trouble?

2023 Year in Review: Business Developments

By Alex Philippidis At the start of 2023, the website for Pfizer CenterOne posted an article titled, “What Trends Will Shape the Pharma and Biotech Industries in 2023?” It quoted Rick L. Knight, the company’s global head of strategic account management, as follows: “We can continue to expect to see…

Continue Reading 2023 Year in Review: Business Developments

COVID Native research, CRISPR for sickle cell

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. How sickle cell became the first CRISPR’d disease Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different…

Continue Reading COVID Native research, CRISPR for sickle cell

Clinical Oncology Next Generation Sequencing Market Size,

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Clinical Oncology Next Generation Sequencing Market – (By Application Type (Screening, Companion Diagnostics, and Other Diagnostics), By End User (Hospitals, Clinics, and Laboratories), By Technology Type (Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing…

Continue Reading Clinical Oncology Next Generation Sequencing Market Size,

DNA Sequence in Pfizer COVID-19 Vaccine Could Spur New Lawsuits: Lawyers

A woman walks by Pfizer’s headquarters in New York City in a file image. (Kena Betancur/AFP via Getty Images) Pfizer and its partner BioNTech could be open to lawsuits for including a DNA sequence in their COVID-19 vaccine. The Public Readiness and Emergency Preparedness Act, known as the PREP Act,…

Continue Reading DNA Sequence in Pfizer COVID-19 Vaccine Could Spur New Lawsuits: Lawyers

Lipid Nanoparticles CDMO Market Size, Share and Growth Factors Study

PRESS RELEASE Published December 1, 2023 The Lipid Nanoparticles CDMO Market (Nucleic Acids LNPs) worth $450.2 Mn by 2030 – Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the ” “Global Lipid Nanoparticles (LNPs) CDMO Market Focus on Nucleic Acids…

Continue Reading Lipid Nanoparticles CDMO Market Size, Share and Growth Factors Study

Pfizer Says Trial of Weight-Loss Drug Meets Primary Endpoint, Will Not Pursue Phase 3 Studies for Twice-Daily Dosage -December 01, 2023 at 08:25 am EST

Pfizer, Inc. the world’s leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines (52.4%); - drugs for the treatment of cancer (15.2%); - cardiovascular, metabolic and analgesic drugs (11.5%); - injectable, anti-infectives drugs and active pharmaceutical ingredients (9%); - drugs for inflammatory and immune…

Continue Reading Pfizer Says Trial of Weight-Loss Drug Meets Primary Endpoint, Will Not Pursue Phase 3 Studies for Twice-Daily Dosage -December 01, 2023 at 08:25 am EST

Pfizer’s stock falls 4% after halting trial of obesity drug due to side effects

Pfizer Inc.’s stock tumbled 6% Friday, after the company said it would not move to a Phase 3 trial of a twice-daily formulation of a weight-loss drug after patients in an earlier study had a lot of side effects. The stock was on track for its biggest one-day percentage decline…

Continue Reading Pfizer’s stock falls 4% after halting trial of obesity drug due to side effects

Pfizer (PFE) says twice-daily danuglipron formulation for obesity will not advance into Phase 3 studies

FREE Breaking News Alerts from StreetInsider.com! StreetInsider.com Top Tickers, 12/1/2023 December 1, 2023 6:57 AM EST Pfizer (NYSE: PFE) says twice-daily danuglipron formulation will not advance into Phase 3 studies Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26…

Continue Reading Pfizer (PFE) says twice-daily danuglipron formulation for obesity will not advance into Phase 3 studies

Texas AG suing Pfizer, says company misrepresented COVID vaccine data

Embattled Texas Attorney General Ken Paxton is suing Pfizer, claiming the company unlawfully misrepresented the effectiveness of its COVID-19 vaccine and tried to censor public discussion of the vaccine.  Paxton said Pfizer engaged in a violation of the Texas Deceptive Trade Practice Act.  At issue was Pfizer and BioNTech saying…

Continue Reading Texas AG suing Pfizer, says company misrepresented COVID vaccine data

Car T Cell Therapy Market will generate new growth opportunities 2023-2030

PRESS RELEASE Published November 29, 2023 The research study conducted by Coherent Market Insights on the “Car T Cell Therapy Market” spans over 100 pages and delves into various facets of this market. It analyzes the business strategies adopted by emerging industry players, examines the geographical scope, dissects market segments,…

Continue Reading Car T Cell Therapy Market will generate new growth opportunities 2023-2030

Software Developer – Backend at European Molecular Biology Laboratory (EMBL)

About the team/job We are looking for an enthusiastic and driven Backend Software Developer to join Open Targets at EMBL-EBI. We are open to applicants at different career stages, but we are keen to find someone who wants to embrace cutting-edge technologies in order to tackle complex challenges in drug…

Continue Reading Software Developer – Backend at European Molecular Biology Laboratory (EMBL)

Survey of Adulterated Sexual Enhancement Products

Introduction In the US, dietary supplements (DS) are not subject to pre-market approval for safety and efficacy by the FDA.1 Post-market surveillance by the FDA has found increasing numbers of supplements to be adulterated or tainted, meaning that they contain undeclared or hidden, unapproved drug ingredients.2,3 These hidden ingredients have…

Continue Reading Survey of Adulterated Sexual Enhancement Products

DNA Contamination In COVID-19 Vaccines May Explain Rise In Cancers, Clots, Autoimmune Diseases: Pathologist

Authored by Tom Ozimek and Jan Jekielek via The Epoch Times (emphasis ours), Clinical pathologist Dr. Ryan Cole has said that DNA contamination in some COVID-19 vaccines may be related to an increase in cancers, micro-clotting, and autoimmune diseases. “My big concern is the fact that billions of people across…

Continue Reading DNA Contamination In COVID-19 Vaccines May Explain Rise In Cancers, Clots, Autoimmune Diseases: Pathologist

EMBL’s European Bioinformatics Institute (EMBL-EBI) in 2023 | Nucleic Acids Research

Abstract The European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) is one of the world’s leading sources of public biomolecular data. Based at the Wellcome Genome Campus in Hinxton, UK, EMBL-EBI is one of six sites of the European Molecular Biology Laboratory (EMBL), Europe’s only intergovernmental life sciences organisation. This…

Continue Reading EMBL’s European Bioinformatics Institute (EMBL-EBI) in 2023 | Nucleic Acids Research

Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

As per the report by Fortune Business Insights, The Biopharmaceuticals Market size is projected to reach USD 799.76 Billion by 2030, at a CAGR of 7.9% during the forecast period. Biopharmaceuticals Market Biopharmaceuticals Market (2023-2030) Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) — The global biopharmaceuticals market size was USD…

Continue Reading Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

[Latest] Global Gene Synthesis Market Size, Forecast, Analysis & Share Surpass US$ 5,879 Million By 2032, At 19% CAGR

Custom Market Insights The Global Gene Synthesis Market was at US$ 1,200 Million in 2022 and is growing to approx US$ 5,879 Million by 2032, with a CAGR growth of 19%, 2023 and 2032. The Global Gene Synthesis Market was estimated at USD 1,200 Million in 2022 and is anticipated…

Continue Reading [Latest] Global Gene Synthesis Market Size, Forecast, Analysis & Share Surpass US$ 5,879 Million By 2032, At 19% CAGR

Blenrep redux? New Phase 3 data revive interest in GSK blood cancer drug – MM+M

GSK blood cancer drug Blenrep, withdrawn from the U.S. market just 12 months ago, may see renewed interest thanks to positive data from a combination trial. The Phase 3 study, dubbed DREAMM-7, showed that Blenrep, a BCMA-directed antibody drug conjugate (ADC), significantly extended the time to disease progression or death…

Continue Reading Blenrep redux? New Phase 3 data revive interest in GSK blood cancer drug – MM+M

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

Continue Reading Phase 3 Trials Reveal New Standards of Care for NSCLC

NOT REAL NEWS: A look at what didn’t happen this week

A roundup of some of the most popular but completely untrue stories and visuals of the week. None of these are legit, even though they were shared widely on social media. The Associated Press checked them out. Here are the facts: ___ No evidence that DNA sequence used in Pfizer…

Continue Reading NOT REAL NEWS: A look at what didn’t happen this week

A look at what didn’t happen this week

FILE – A health worker administers a dose of COVID-19 vaccine during a vaccination clinic in Reading, Pa. On Friday, Nov. 24, 2023, The Associated Press reported on stories circulating online incorrectly claiming Pfizer’s COVID-19 vaccine contains a DNA sequence called Simian Virus 40 that can cause health problems, including…

Continue Reading A look at what didn’t happen this week

Global Diffuse Large B-cell Lymphoma Therapeutics Market

Global Diffuse Large B-cell Lymphoma Therapeutics Market Forecast 2023-2032 The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2023 identifies the increasing incidence…

Continue Reading Global Diffuse Large B-cell Lymphoma Therapeutics Market

Nova Scotia worker can’t prove religious reasons for refusing vaccine

On Sept. 9, 2021, Securitas posted a memo to employees advising that the federal government had announced that COVID-19 vaccination would be mandatory for employees in the air transport industry. As a result, Securitas employees were required to be fully vaccinated by the end of October 2021 and those who…

Continue Reading Nova Scotia worker can’t prove religious reasons for refusing vaccine

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

Posts Spread False Claim About Moderna Patent Application

SciCheck Digest The mRNA COVID-19 vaccines — like many other vaccines — can contain small amounts of DNA left over from the manufacturing process. There’s no evidence this residual DNA causes “turbo cancer,” or very aggressive cancer. Nor did Moderna admit that “mRNA Jabs Cause Turbo-Cancer,” contrary to an online…

Continue Reading Posts Spread False Claim About Moderna Patent Application

First ever CRISPR gene therapy approval: What happens next?

Published: Nov 22, 2023 By Greg Slabodkin, Lori Ellis, Heather McKenzie Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) ⁠approved CRISPR/Cas9⁠ gene-edited therapy exagamglogene autotemcel (exa-cel). Will the FDA follow suit? What can patients expect the price tag to…

Continue Reading First ever CRISPR gene therapy approval: What happens next?

Herpes Zoster Pipeline Analysis Demonstrates Novel 18+

Herpes Zoster Pipeline DelveInsight’s, “Herpes Zoster Pipeline Insight 2023,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Herpes Zoster pipeline landscape. It covers the Herpes Zoster pipeline drug profiles, including Herpes Zoster clinical trials and nonclinical stage products. It also covers the therapeutics assessment by…

Continue Reading Herpes Zoster Pipeline Analysis Demonstrates Novel 18+

Xtandi Approved for Nonmetastatic Castration-Sensitive Prostate Cancer

The US Food and Drug Administration (FDA) has approved the supplemental new drug application for Xtandi (enzalutamide) for the treatment of patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) and biochemical recurrence at high risk for metastasis.  The approval was based on data from the phase 3 EMBARK trial (ClinicalTrials.gov Identifier:…

Continue Reading Xtandi Approved for Nonmetastatic Castration-Sensitive Prostate Cancer